Literature DB >> 17609987

Remission of membranoproliferative glomerulonephritis type I with the use of tacrolimus.

Maha Haddad1, Keith Lau, Lavjay Butani.   

Abstract

Membranoproliferative glomerulonephritis, albeit uncommon, is associated with considerable morbidity and mortality in children. Corticosteroids are the mainstay of therapy for severe disease, although data supporting their use are limited. We report our experience in treating two children with nephrotic-nephritic syndrome from idiopathic membranoproliferative glomerulonephritis. Both children experienced a suboptimal response to prolonged courses of steroids and were started on tacrolimus as a steroid-sparing agent. Rapid and complete remission was achieved in both children after initiation of tacrolimus. The purpose of our report is to increase awareness of health care professionals to the potential benefits of this agent in inducing remission in children with severe membranoproliferative glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609987     DOI: 10.1007/s00467-007-0523-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  18 in total

1.  FK506 in the treatment of children with nephrotic syndrome of different pathological types.

Authors:  Z Xia; G Liu; Y Gao; Z Fan; Y Fu; L F Zhang; X Ren; C Gao
Journal:  Clin Nephrol       Date:  2006-08       Impact factor: 0.975

2.  Idiopathic membranoproliferative glomerulonephritis in children. Report of 105 cases.

Authors:  R Habib; C Kleinknecht; M C Gubler; M Levy
Journal:  Clin Nephrol       Date:  1973 Jul-Aug       Impact factor: 0.975

3.  Severe recurrence of type I membranoproliferative glomerulonephritis after transplantation: remission on steroids and cyclophosphamide.

Authors:  R Cahen; P Trolliet; F Dijoud; K Megri; B François
Journal:  Transplant Proc       Date:  1995-04       Impact factor: 1.066

4.  Membranoproliferative glomerulonephritis in childhood: factors affecting prognosis.

Authors:  S Arslan; U Saatci; S Ozen; A Bakkaloğlu; N Besbas; K Tinaztepe; M Hayran
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

5.  Recurrent type I membranoproliferative glomerulonephritis after renal transplantation and protective role of cyclosporine in acute crescentic transformation.

Authors:  N Ahsan; E C Manning; D J Dabbs; R R Gifford; H C Yang
Journal:  Clin Transplant       Date:  1997-02       Impact factor: 2.863

6.  Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation.

Authors:  Richard Trompeter; Guido Filler; Nicholas J A Webb; Alan R Watson; David V Milford; Gunnar Tyden; Ryszard Grenda; Jan Janda; David Hughes; Jochen H H Ehrich; Bernd Klare; Graziella Zacchello; Inge Bjorn Brekke; Mary McGraw; Ferenc Perner; Lucian Ghio; Egon Balzar; Styrbjörn Friman; Rosanna Gusmano; Jochen Stolpe
Journal:  Pediatr Nephrol       Date:  2002-03       Impact factor: 3.714

7.  Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants.

Authors:  G Filler; R Grygas; I Mai; H J Stolpe; C Greiner; S Bauer; J H Ehrich
Journal:  Nephrol Dial Transplant       Date:  1997-08       Impact factor: 5.992

8.  Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis.

Authors:  Janette C Cansick; Rachel Lennon; Carole L Cummins; Alexander J Howie; Mary E McGraw; Moin A Saleem; E Jane Tizard; Sally-Anne Hulton; David V Milford; C Mark Taylor
Journal:  Nephrol Dial Transplant       Date:  2004-09-22       Impact factor: 5.992

Review 9.  Mesangiocapillary glomerulonephritis.

Authors:  G D'Amico; F Ferrario
Journal:  J Am Soc Nephrol       Date:  1992-04       Impact factor: 10.121

10.  Cyclosporin A treatment for membranoproliferative glomerulonephritis type II.

Authors:  Takahiro Kiyomasu; Minoru Shibata; Hideo Kurosu; Kazuhiro Shiraishi; Hisako Hashimoto; Tadashi Hayashidera; Yuichi Akiyama; Nobuaki Takeda
Journal:  Nephron       Date:  2002-07       Impact factor: 2.847

View more
  5 in total

Review 1.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

Review 2.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

3.  Remission of resistant MPGN type I with mycophenolate mofetil and steroids.

Authors:  Sudarsana De; Dana Al-Nabhani; Paul Thorner; Daniel Cattran; Tino D Piscione; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2008-10-30       Impact factor: 3.714

4.  Dense deposit disease and the factor H H402 allele.

Authors:  Keith K Lau; Richard J Smith; Peter C Kolbeck; Lavjay Butani
Journal:  Clin Exp Nephrol       Date:  2008-01-26       Impact factor: 2.801

Review 5.  Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.

Authors:  Michael Rudnicki
Journal:  Biomed Res Int       Date:  2017-05-09       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.